Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chaigui Granules phase IIb trial in mild-to-moderate major depressive disorder
ChiCTR2600131999Phase 2Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Chaigui Granules in major depressive disorder (MDD) (4 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Reduction in HAMD-17 total score from baseline at week 8. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Chaigui Granules
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600131999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131999.